Literature DB >> 30228704

Prostate Cancer: Update on Early Detection and New Biomarkers.

Robert L Grubb1.   

Abstract

Screening and early treatment of prostate cancer (PCa) has recently come under scrutiny due to the rates of overdiagnosis of low risk cancer. Randomized trials, including ERSPC and PLCO, have informed our understanding of the survival benefit provided by systematic PCa screening with serum prostate-specific antigen (PSA). To reduce the number of patients diagnosed with indolent disease, new adjuvant risk stratification tests have become available.

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30228704      PMCID： PMC6139871     

Source DB:  PubMed          Journal:  Mo Med        ISSN： 0026-6620


  20 in total

1.  Serum prostate-specific antigen for the early detection of prostate cancer: always, never, or only sometimes?

Authors:  Peter R Carroll; Jared M Whitson; Matthew R Cooperberg
Journal:  J Clin Oncol       Date:  2010-12-28       Impact factor: 44.544

2.  Comorbidity and mortality results from a randomized prostate cancer screening trial.

Authors:  E David Crawford; Robert Grubb; Amanda Black; Gerald L Andriole; Ming-Hui Chen; Grant Izmirlian; Christine D Berg; Anthony V D'Amico
Journal:  J Clin Oncol       Date:  2010-11-01       Impact factor: 44.544

3.  More on Reevaluating PSA Testing Rates in the PLCO Trial.

Authors:  Paul Pinsky; Philip Prorok
Journal:  N Engl J Med       Date:  2016-10-13       Impact factor: 91.245

4.  Reevaluating PSA Testing Rates in the PLCO Trial.

Authors:  Jonathan E Shoag; Sameer Mittal; Jim C Hu
Journal:  N Engl J Med       Date:  2016-05-05       Impact factor: 91.245

5.  Assessing contamination and compliance in the prostate component of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.

Authors:  Paul F Pinsky; Amanda Blacka; Barnett S Kramer; Anthony Miller; Philip C Prorok; Christine Berg
Journal:  Clin Trials       Date:  2010-06-22       Impact factor: 2.486

6.  The impact of PLCO control arm contamination on perceived PSA screening efficacy.

Authors:  Roman Gulati; Alex Tsodikov; Elisabeth M Wever; Angela B Mariotto; Eveline A M Heijnsdijk; Jeffrey Katcher; Harry J de Koning; Ruth Etzioni
Journal:  Cancer Causes Control       Date:  2012-04-10       Impact factor: 2.506

7.  Cancer Statistics, 2017.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2017-01-05       Impact factor: 508.702

8.  Mortality results from a randomized prostate-cancer screening trial.

Authors:  Gerald L Andriole; E David Crawford; Robert L Grubb; Saundra S Buys; David Chia; Timothy R Church; Mona N Fouad; Edward P Gelmann; Paul A Kvale; Douglas J Reding; Joel L Weissfeld; Lance A Yokochi; Barbara O'Brien; Jonathan D Clapp; Joshua M Rathmell; Thomas L Riley; Richard B Hayes; Barnett S Kramer; Grant Izmirlian; Anthony B Miller; Paul F Pinsky; Philip C Prorok; John K Gohagan; Christine D Berg
Journal:  N Engl J Med       Date:  2009-03-18       Impact factor: 91.245

9.  Multicenter Evaluation of the Prostate Health Index to Detect Aggressive Prostate Cancer in Biopsy Naïve Men.

Authors:  Claire de la Calle; Dattatraya Patil; John T Wei; Douglas S Scherr; Lori Sokoll; Daniel W Chan; Javed Siddiqui; Juan Miguel Mosquera; Mark A Rubin; Martin G Sanda
Journal:  J Urol       Date:  2015-01-28       Impact factor: 7.450

10.  Prostate-specific antigen-based screening: controversy and guidelines.

Authors:  Eric H Kim; Gerald L Andriole
Journal:  BMC Med       Date:  2015-03-24       Impact factor: 8.775
View more
  1 in total

1.  Proteolyzed Variant of IgG with Free C-Terminal Lysine as a Biomarker of Prostate Cancer.

Authors:  Anna Lokshin; Lyudmila M Mikhaleva; Eugene I Goufman; Marina N Boltovskaya; Natalia B Tikhonova; Irina I Stepanova; Alexandr A Stepanov; Natalia V Potoldykova; Andrey Z Vinarov; Paul Stemmer; Vasily Iakovlev
Journal:  Biology (Basel)       Date:  2021-08-23
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.